Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity.
Polyaspartic Acid (PAA) protects the kidney from experimental gentamicin nephrotoxicity despite large increases in renal cortical gentamicin content. In these experiments, prominent cytoplasmic vacuoles were noted in all animals that received PAA with or without gentamicin. The present study showed that there were no renal structural or functional consequences of PAA given alone or with gentamicin for up to 14 days, followed by a 16-week washout period. Creatinine clearance was similar to that of controls in animals that received gentamicin and in those that received PAA alone. Thus, complete functional protection was conferred by PAA and gentamicin, confirming previous reports from our laboratory. There was no protection by PAA from the nephrotoxic effects of mercuric chloride and cis-platinum.
Swan
S K
SK
Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland 97201.
Kohlhepp
S J
SJ
Kohnen
P W
PW
Gilbert
D N
DN
Bennett
W M
WM
D000818:Animals; D002945:Cisplatin / Q000037:antagonists & inhibitors; D003404:Creatinine / Q000652:urine; D005839:Gentamicins / Q000037:antagonists & inhibitors* / Q000633:toxicity; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008627:Mercuric Chloride / Q000037:antagonists & inhibitors; D010455:Peptides / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344
D005839:Gentamicins; D010455:Peptides; C017645:polyaspartate; D008627:Mercuric Chloride; D003404:Creatinine; D002945:Cisplatin